Liquidia Sinks 5% After Recent Rally
Liquidia Corporation shares were flat in early trading Tuesday after falling hard the day before. Investors are watching for more news from the company on YUTREPIA, its inhaled drug for lung disease. The Nasdaq stock ended Monday at $58.75, off 5.04%, and was last seen at $58.91 in thin premarket action at 6:22 a.m. EDT, according to MarketWatch. Liquidia has been a top biotech pick for 2026, with the stock gaining about 70% year to date through Monday, Yahoo Finance data show. Shares touched an intraday high of $63.46 last week before pulling back.
